PMID- 15804266
OWN - NLM
STAT- MEDLINE
DCOM- 20050520
LR  - 20151113
IS  - 1351-5101 (Print)
IS  - 1351-5101 (Linking)
VI  - 12
IP  - 5
DP  - 2005 May
TI  - Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of 
      cobalamin and folate administration.
PG  - 365-8
AB  - Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment 
      and dementia. L-dopa treatment may represent an acquired cause of 
      hyperhomocysteinemia (HHcy), as evidenced by studies in rats as well as in 
      Parkinson's disease (PD) patients. Folate and cobalamin status also seems to 
      influence the effects of L-dopa on plasma Hcy levels; therefore B-vitamins 
      supplementation has been proposed to reduce the HHcy in L-dopa treated PD 
      patients. Plasma Hcy, folate, and cobalamin levels were evaluated in 20 PD 
      patients treated with L-dopa in the baseline condition and following a 5-week 
      period of treatment with cobalamin and folate; results were compared with 35 
      controls. Analysis of data revealed that Hcy levels were higher in L-dopa treated 
      PD patients when compared with age- and sex-matched controls and that 
      supplementation of the diet with cobalamin and folate is effective in reducing 
      Hcy concentrations; these findings may have important implications in the 
      treatment of PD patients who are potentially at risk for vascular diseases and 
      cognitive impairment or dementia.
FAU - Lamberti, P
AU  - Lamberti P
AD  - Department of Neurological Sciences, University of Bari, Ospedale Policlinico, 
      Bari, Italy. lamberti@neurol.uniba.it
FAU - Zoccolella, S
AU  - Zoccolella S
FAU - Armenise, E
AU  - Armenise E
FAU - Lamberti, S V
AU  - Lamberti SV
FAU - Fraddosio, A
AU  - Fraddosio A
FAU - de Mari, M
AU  - de Mari M
FAU - Iliceto, G
AU  - Iliceto G
FAU - Livrea, P
AU  - Livrea P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Antiparkinson Agents)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 46627O600J (Levodopa)
RN  - 935E97BOY8 (Folic Acid)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Aged
MH  - Antiparkinson Agents/*adverse effects
MH  - Female
MH  - Folic Acid/blood/*therapeutic use
MH  - Homocysteine/blood
MH  - Humans
MH  - Hyperhomocysteinemia/blood/etiology/*prevention & control
MH  - Levodopa/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/blood/drug therapy
MH  - Vitamin B 12/blood/*therapeutic use
EDAT- 2005/04/05 09:00
MHDA- 2005/05/21 09:00
CRDT- 2005/04/05 09:00
PHST- 2005/04/05 09:00 [pubmed]
PHST- 2005/05/21 09:00 [medline]
PHST- 2005/04/05 09:00 [entrez]
AID - ENE973 [pii]
AID - 10.1111/j.1468-1331.2004.00973.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2005 May;12(5):365-8. doi: 10.1111/j.1468-1331.2004.00973.x.